This is a StreetInsider.com Premium Only Page

(PDSB) –

Apr 23, 2024 08:00 AM PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic

Apr 18, 2024 04:16 PM Form PRE 14A PDS Biotechnology Corp For: Jun 24

Mar 28, 2024 05:27 PM Form S-8 PDS Biotechnology Corp

Mar 28, 2024 05:19 PM Form 10-K PDS Biotechnology Corp For: Dec 31

Mar 28, 2024 07:42 AM PDS Biotechnology Corp (PDSB) PT Lowered to $11 at B.Riley on 1+ year delay

Mar 27, 2024 07:32 AM PDS Biotechnology (PDSB) Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Mar 27, 2024 07:31 AM Form 8-K PDS Biotechnology Corp For: Mar 27

Mar 27, 2024 07:30 AM PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Mar 20, 2024 08:00 AM PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

Mar 13, 2024 08:00 AM PDS Biotechnology (PDSB) Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune

Mar 13, 2024 08:00 AM PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

Mar 13, 2024 06:03 AM Form 8-K PDS Biotechnology Corp For: Mar 13

Jan 29, 2024 05:28 PM Form SC 13G PDS Biotechnology Corp Filed by: BlackRock Inc.

Jan 23, 2024 04:34 PM Form 4 PDS Biotechnology Corp For: Jan 22 Filed by: Shepard Kirk V.

Jan 23, 2024 04:31 PM Form 3 PDS Biotechnology Corp For: Jan 22 Filed by: Shepard Kirk V.

Jan 22, 2024 05:10 PM Form 8-K PDS Biotechnology Corp For: Jan 22

Jan 22, 2024 04:46 PM PDS Biotechnology (PDSB) Appoints Kirk V. Shepard as Chief Medical Officer

Jan 22, 2024 04:46 PM PDS Biotechnology (PDSB) Appoints Kirk V. Shepard as Chief Medical Officer

Jan 22, 2024 04:45 PM PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Jan 16, 2024 08:00 AM PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

Dec 4, 2023 06:15 PM Form 4 PDS Biotechnology Corp For: Dec 04 Filed by: Boesgaard Lars

Dec 4, 2023 06:12 PM Form 3 PDS Biotechnology Corp For: Dec 04 Filed by: Boesgaard Lars

Dec 4, 2023 04:50 PM PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2023 04:03 PM Form 8-K PDS Biotechnology Corp For: Dec 04

Nov 28, 2023 08:31 AM Apyx Medical Corp. (APYX) names Matthew Hill CFO

Nov 28, 2023 08:30 AM Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

Nov 28, 2023 07:31 AM PDS Biotechnology (PDSB) Appoints Lars Boesgaard as Chief Financial Officer

Nov 28, 2023 07:30 AM PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

Nov 28, 2023 06:29 AM Form 8-K PDS Biotechnology Corp For: Nov 21

Nov 15, 2023 07:36 AM PDS Biotechnology Corp (PDSB) PT Lowered to $20 at Oppenheimer

Nov 14, 2023 08:48 PM Form S-8 PDS Biotechnology Corp

Nov 14, 2023 05:23 PM Form 10-Q PDS Biotechnology Corp For: Sep 30

Nov 14, 2023 07:48 AM Form 8-K PDS Biotechnology Corp For: Nov 14

Nov 14, 2023 07:33 AM PDS Biotechnology (PDSB) Tops Q3 EPS by 10c

Nov 14, 2023 07:30 AM PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023 04:09 PM Form 8-K PDS Biotechnology Corp For: Nov 09

Nov 9, 2023 08:03 AM PDS Biotechnology (PDSB) Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy

Nov 9, 2023 08:00 AM PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na

Nov 7, 2023 08:00 AM PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

Oct 23, 2023 04:07 PM Form 8-K PDS Biotechnology Corp For: Oct 23

Oct 23, 2023 08:07 AM PDS Biotechnology (PDSB) Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Oct 23, 2023 08:00 AM PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Oct 11, 2023 04:02 PM Form 8-K PDS Biotechnology Corp For: Oct 11

Oct 11, 2023 08:02 AM PDS Biotechnology (PDSB) Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial of PDS0301

Oct 11, 2023 08:00 AM PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Oct 3, 2023 04:04 PM Form 8-K PDS Biotechnology Corp For: Oct 03

Oct 3, 2023 04:03 PM Form 8-K PDS Biotechnology Corp For: Oct 03

Oct 3, 2023 09:03 AM Form 8-K PDS Biotechnology Corp For: Oct 03

Oct 3, 2023 07:01 AM PDS Biotechnology (PDSB) Reports Interim 24-Month Survival Rate of 74% with PDS0101 in Combination with KEYTRUDA

Oct 3, 2023 07:00 AM PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)